Growth Retardation Clinical Trial
Official title:
Effect of Nutritional Formula Supplementation on Growth Rate of Growth Hormone (GH) Treated Children With Growth Hormone Deficiency (GHD) After the Second Year of Therapy- a Randomized Double Blind, Placebo Controlled Trial
The Proposed study is a double blind, randomized, placebo controlled study The aim of the study is to evaluate the effect of combined Growth Hormone (GH) treatment & nutritional formula supplementation versus GH & placebo on growth parameters in 64 children with Isolated Growth Hormone Deficiency (IGHD) after the 2nd year of GH treatment. In this trial GH is a background treatment (non-investigational medicinal product. Participants may be treated with any of the commercial GH products approved in Israel for the indication of IGHD. Participants will be randomly assigned either to the intervention group or the placebo control group. Randomization for the two study groups will be made in a ratio of 1:1. Both participants and study team will be blinded to the type of treatment that each patient will receive during the study. The randomization will be done according to gender and tanner stage. Participants in the intervention groups will be treated with the study formulas and participants in the control group will be treated with a placebo low caloric formulas (Powder added to water) The study will continue for 6 months of intervention versus active placebo, with additional 6 months (an extension period), in which participants at both groups, the intervention and the placebo, will be offered to continue their participation in the study with the active study supplement.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02249754 -
Nutrition Education Package for Infants and Young Child Feeding and Health in Rural Tanzania
|
N/A | |
| Completed |
NCT02438774 -
Intervention in Minimizing Aflatoxins and Fumonisins Exposure to Children Through Food and Breastfeeding in Tanzania
|
N/A | |
| Completed |
NCT03217045 -
Nutrition Protocol and Premature Infants' Growth
|
||
| Recruiting |
NCT04294368 -
Targeted Fortification of Donor Breast Milk in Preterm Infants
|
N/A | |
| Completed |
NCT02716935 -
Prebiotics and Microbiota Composition and Functionality in Rural Burkinabe Infants
|
N/A | |
| Completed |
NCT02403739 -
Visual Interpretation of Neonatal Growth Charts
|
N/A | |
| Completed |
NCT02236468 -
Creating Homestead Agriculture for Nutrition and Gender Equity (CHANGE) in Burkina Faso
|
N/A | |
| Not yet recruiting |
NCT01494779 -
Evaluation of Pharmacokinetic and Pharmacodynamic Parameters of Somatropin Produced by Laboratory Blausiegel Indústria e Comércio Ltda., Compared to Saizen® From Laboratory Merck Serono S.A.
|
Phase 1 | |
| Completed |
NCT05946928 -
EMERGENCE AGITATION After Premedication IN PAEDIATRIC MAGNETIC RESONANCE IMAGING: A RETROSPECTIVE COHORT STUDY
|
||
| Recruiting |
NCT03290235 -
Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children
|
Phase 4 | |
| Completed |
NCT02259166 -
Enhanced Homestead Food Production Plus+ Program in the Lake Zone, Tanzania
|
N/A | |
| Recruiting |
NCT06071403 -
The Effects of Time Points to Cease Parenteral Nutrition and IGF-1 on Very Low Birth Weight Infants
|
||
| Completed |
NCT05640596 -
Antenatal Corticosteroid Therapy: Which Impact on Birth Parameters?
|
||
| Completed |
NCT04633135 -
Research on Emissions, Air Quality, Climate and Cooking Technologies in Northern Ghana
|
N/A | |
| Completed |
NCT00174278 -
Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary
|
Phase 3 | |
| Recruiting |
NCT05518188 -
Melpida: Recombinant Adeno-associated Virus (Serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)
|
Phase 1/Phase 2 | |
| Completed |
NCT03635944 -
Nutritional Care and Head Growth in Preterm Infants
|
||
| Completed |
NCT00813189 -
Efficacy Study of Recombinant Growth Hormone on Muscle Function in Children Long-term Treated With Glucocorticoid
|
Phase 3 |